Atlas Trials

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Clinical trial NCT07480863 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07480863
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone Lymphoma(MZL)
Start date
2025-10-01
Primary completion
2029-10-01
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.